Pulminiq Inhaled Cyclosporine Approval Will Be Delayed
This article was originally published in The Pink Sheet Daily
Executive Summary
Chiron expects approval of the inhaled cyclosporine Pulminiq to be delayed by three months while FDA reviews additional analyses of pivotal data
You may also be interested in...
Chiron Pulminiq Gets Pulmonary-Allergy Committee Review June 6
Advisory committee review of the immunosuppressant will likely focus on FDA-requested analysis of pivotal data for the lung transplant treatment. Chiron confirms that FDA extended Pulminiq's user fee action date by 90 days, to July 15.
Chiron Pulminiq Gets Pulmonary-Allergy Committee Review June 6
Advisory committee review of the immunosuppressant will likely focus on FDA-requested analysis of pivotal data for the lung transplant treatment. Chiron confirms that FDA extended Pulminiq's user fee action date by 90 days, to July 15.
Chiron’s Fluvirin Distribution Contracts Under Discussion
The company and its vaccine distributors will determine whether contracts for 2004 will be extended for the next flu season given uncertainty over whether Fluvirin will be available. Additional clarity on Fluvirin supply is expected in “early spring.”